Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 4/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13332631 | 0.88 | GAA (0.43) | MEN1GAAKMT2AFOXO1SCN9A | |
| SCHEMBL3311810 | 0.86 | MEN1 (0.42) | MEN1GAAKMT2AFOXO1MAPK1 | |
| SCHEMBL13332995 | 0.86 | MEN1 (0.46) | MEN1GAAKMT2AFOXO1SCN9A | |
| SCHEMBL13332624 | 0.79 | TNF (0.52) | MEN1GAAKMT2ACNR2 | |
| SCHEMBL13332622 | 0.75 | MEN1 (0.40) | MEN1GAAKMT2AFOXO1MAPK1 | |
| SCHEMBL13332994 | 0.74 | MEN1 (0.43) | MEN1GAAKMT2AFOXO1MAPK1 | |
| SCHEMBL13332466 | 0.73 | MEN1 (0.38) | MEN1GAAKMT2AFOXO1SHMT2 | |
| SCHEMBL3312312 | 0.70 | MEN1 (0.46) | MEN1GAAKMT2AFOXO1SMN1; SMN2 | |
| SCHEMBL3311607 | 0.70 | TOP2A (0.32) | — | |
| SCHEMBL13332752 | 0.69 | MEN1 (0.45) | MEN1GAAKMT2AFOXO1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2138482-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2009-12-30 | — | — | EP | disclosed |
| EP-2138482-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | P2RY12, P2RY4, P2RY1 | MEN1 3655/4885GAA 4306/4885KMT2A 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.